From clinical trial saturation to a suspiciously strong placebo effect: Here are some of the major challenges facing biopharma companies in pursuit of the first FDA-approved therapy for non-alcoholic steatohepatitis (NASH).
Gilead has released some early proof-of-concept data for its investigational ACC inhibitor for NASH, acquired in 2016 for $400 million and up to $800 million more in milestone payments.
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.
After a decade at the helm, Organovo's Keith Murphy is stepping down, to be replaced by eStudySite's Taylor Crouch. It marks a new era of commercialization for the San Diego company that has long been a pioneer in the 3D bioprinting of tissues and organs.